For any interest in Pathelen, please send us an email via the contact page


We provide medical product Wholesale services to The police and Military, the Private and Public Sector including selected Distribution Companies


We predominately work with Medical Device products on a exclusive, licensed basis within different territories. All UniPharma products are registered with local FDA's in all our territories with South Africa on the way.


We supply products directly from source to the client or through our chosen distribution partners


UniPharma is a newly formed company, licensed to market, and supply Pathelen in Ghana, Nigeria, South Africa and projectively the wider African continent.

We are focused on solving the issue of anti-microbial resistance in open wounds, preventing suffering, help treating patients rapidly, effectively, cheaply and saving millions of lives.






Supporting the World to solve the Anti-Microbial Resistance Crisis

Pathelen® Woundpowder (European Class 1 Certified, Ghana FDA and Nigeria NAFDAC Approved Medical Device), a pioneering, side effect free treatment for open wound infections like MRSA, MDR, ESBL, and antibiotic-resistant bacteria (Superbugs), advancing existing capabilities of wound-care in public, private and military hospitals.

Pathelen Gel, Pathelen Plasters and pH Booster Spray


Pathelen® Woundpowder is a Class 1 medical device, specifically designed and developed for the treatment of multi-resistant bacteria (such as MRSA) in open wounds. Vitally, bacteria are unable to develop resistance to it, in contrast to all antibiotics designed to perform a similar function.

Pathelen® eliminates most external bacterial wound infections within 5-10 days in most cases such as preparing for a wound closure surgery or enhancing the growth of granulating tissue on the treated wound.

It has a wide range of antimicrobial uses, highly effective in combating gram-positive and gram-negative aerobic and anaerobic micro-organisms (clostridial and non-clostridial in composition with aerobic and facultative anaerobic).

Germs which can be typically treated with Pathelen® are:
Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus (MRSA), Enterobacteria i.e. – Escherichia coli – Klebsiella pneumoniae – Klebsiella oxytoca, Proteus mirabilis, Non-fermenting organisms i.e.  Pseudomonas aeruginosa – Acinetobacter baumannii – Pseudomonas

Key Pharmaceutical Properties

Clinical practice shows that the current, individual use of other antimicrobial agents in the treatment of purulo-inflammatory diseases and purulent wounds, does not always lead to the desired result. Additionally, misuse of antibiotics has contributed to the emergence of resistant (hospital) strains of pathogenic micro-organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and become a serious challenge for modern medicine.

Pathelen® can solve this problem, utilising new compositions based on highly dispersed silicas and polymethylsiloxane which have enhanced absorptive, anti-inflammatory and wound-healing abilities for the treatment of a wide range of diseases caused by pathogenic micro-organisms, in particular, purulent wounds.

The intensity of the regeneration process and healing of infected ulcers and wounds depends largely on the speed with which they are cleared of pus and necrotic tissues. Applique sorption, a method of wound healing in which an absorbent in powder form is applied to the wound as a dressing, greatly accelerates this process. This absorption detoxification restores the integrity of the skin and mucous membranes by the removal of microbial cells, bacterial toxins and toxic metabolites of wound fluid and wound cavities in direct contact with the surface of Pathelen®.

Another important therapeutic factor in the first phase of wound healing is dehydration, i.e. absorption of fluid from the wound cavity and perifocal tissues. Hydrophilic highly dispersed silica (HDS) can be used in the first phase of wound healing. Its detoxifying action is due to the absorption of pathogenic protein substances (up to 800 mg/g), including microbial enzymes, exo- and endotoxins (Lipopolysaccharides) and micro-organisms.

Innovative & Unique Treatment

Pathelen® is a pioneering new treatment for a wide range of wounds in soft tissues with aerobic and anaerobic infections, for previously incurable wounds and for common chronic wound diseases including:

Exudating wounds

Chronic pressure ulcers

Venous leg ulcers

Diabetic/neuropathic ulcers

Fungating, cancerous or malignant lesions and wounds with necrotic tissue

Burn wounds

Pathelen® can prevent bacterial infections in post-op wound treatment and has haemostatic action (a process which causes bleeding to stop).

Some strains of MRSA are resistant to all kinds of antibiotics. Pathelen®, due to its affinity to proteins, heals uniquely by agglutinating (clumping together) microorganisms which have protein molecules on the surface.

Through its revolutionary strategy, a local physical absorption treatment of wound bacteria is used instead of the traditional approach of a systemic antibiotic treatment. Pathelen® can even successfully treat ongoing, irreparable wound infections, which are "protected" by a biofilm, or wounds which are contaminated with antibiotic resistant MRSA and extended spectrum beta lactamases (ESBL) producing bacteria like E. coli and Klebsiella.

The most typical problems of patients with these wounds are:

Rapid destruction of tissue

Slow detersion of a wound 

Increase of infectious and inflammatory process (SIRS, sepsis)

The unique effect of Pathelen is achieved through various simultaneous mechanisms:

Elimination of the biofilmc 

Sorption of necrotic tissues

Sorption of pus and toxins (including large amounts of problematic lipopolysaccharides) 

Preparation of a physiological wound environment with granulating tissue


 %        FDA-CODE       CAS No              Function

Aerosil 300Pharma

64%           A2C        7631-86-9         Active Substance

Aerosil R972 Pharma

35.9%                       68 611-44-9      Active Substance

Benzalkonium Chloride

0.1%                          63449-41-2       Surfactant

Why is Pathelen so Effective?

Rapidly removes toxins from any wound and heals it

Bacteria can’t develop resistance

Blocks corrosive properties of saliva and lymph

Very high sorption and does not penetrate the blood circle

Removes bacteria and prevents it from re-entering the wound

Efficiently eliminates the multi-resistant bacteria flora

Destroys micro-organism optimal living conditions

Inhibits surface and intracavitary bleeding

Reduces risk of sepsis and considerably reduces infection

Decreases exotoxins production

Can be used with other medicines and has no known side effects

Easy to store and use requires minimal training


After being introduced to Pathelen, both staff and patients refer to Pathelen as Magic Powder. It's done amazing wonders for my patients."

KO NafulHead of Plastic, Burns & Reconstructive Surgery (37 Hospital Accra)

The efficiency of Pathelen is very remarcable"

Dr. A. Olukayodele Iyun, FWACS, MSc Burn Unit (London), Cert. Cronic Wound Care IIWCC (Stellenbosch)Consultant Plastic Surgeon

With Multiple Drug Resistance (MDR) posing a threat to the management of chronic wounds, the emergence of Pathelen is timely and will go a long way to promote the healing process of chronic wounds as a specialist familiar with the effectiveness of many wound dressing products, I am confident the introduction of Pathelen to the African Market will be a breakthrough. Demand for the product is high as our patients and health workers have seen the effectiveness of this product. It is highly recommendable."

Benson Owusu (RN, BSN, MPH, PM,PR, PHD cand)CEO - Quick Medical Consult


Thomas Proxa

CEO / Co-Founder

Paolo Schulz

COO / Co-Founder

Eric Ofori-Atta

CCO & CDO / Co-Founder

Paul Etomi

CEO Nigeria

Jay Joshi


Louis Abdilla

Chief Relations Officer

Mark Runievicz


Jason Rivera

MD Unitas Group US

Gilles Menguy

Company Lawyer

Dr Ismail Oyebamire

Medical Director

Emmanuel Martey

Distribution Administrator Ghana


Pathelen Health Care AG
PHC AG is a highly funded organisation founded in 2008 by Andreas Tausch, a biochemist and philanthropist.

He conceived the unique and ground-breaking Pathelen formula, which has changed the way we approach wound treatment. Subsequently, Pathelen has been refined, tested and patented to its present highly marketable status and been the subject of thousands of successful case studies over a number of years. Although Pathelen has been the initial focus of the company, other equally effective products are pending release.

UniPharma have a strong personal and contractual relationship with PHC AG and are heavily aligned in making Pathelen available for a highly successful treatment in many forms.